Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary

go back to reference Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355(24):2558–2573. doi:10.1056/NEJMra062453 CrossRefPubMed Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355(24):2558–2573. doi:10.​1056/​NEJMra062453 CrossRefPubMed

go back to reference Melmed S (2016) Pituitary medicine from discovery to patient-focused outcomes. J Clin Endocrinol Metab 101(3):769–777. doi:10.1210/jc.2015-3653 CrossRefPubMedPubMedCentral Melmed S (2016) Pituitary medicine from discovery to patient-focused outcomes. J Clin Endocrinol Metab 101(3):769–777. doi:10.​1210/​jc.​2015-3653 CrossRefPubMedPubMedCentral

go back to reference Lopes MBS (2010) Growth hormone-secreting adenomas: pathology and cell biology. Neurosurg Focus 29(4):E2. doi:10.3171/2010.7.FOCUS10169 CrossRefPubMed Lopes MBS (2010) Growth hormone-secreting adenomas: pathology and cell biology. Neurosurg Focus 29(4):E2. doi:10.​3171/​2010.​7.​FOCUS10169 CrossRefPubMed

go back to reference Osamura RY, Kajiya H, Takei M, Egashira N, Tobita M, Takekoshi S, Teramoto A (2008) Pathology of the human pituitary adenomas. Histochem Cell Biol 130(3):495–507. doi:10.1007/s00418-008-0472-1 CrossRefPubMedPubMedCentral Osamura RY, Kajiya H, Takei M, Egashira N, Tobita M, Takekoshi S, Teramoto A (2008) Pathology of the human pituitary adenomas. Histochem Cell Biol 130(3):495–507. doi:10.​1007/​s00418-008-0472-1 CrossRefPubMedPubMedCentral

go back to reference Kiseljak-Vassiliades K, Shafi S, Kerr JM, Phang TL, Kleinschmidt-DeMasters BK, Wierman ME (2012) Clinical implications of growth hormone-secreting tumor subtypes. Endocrine 42(1):18–28. doi:10.1007/s12020-012-9660-9 CrossRefPubMed Kiseljak-Vassiliades K, Shafi S, Kerr JM, Phang TL, Kleinschmidt-DeMasters BK, Wierman ME (2012) Clinical implications of growth hormone-secreting tumor subtypes. Endocrine 42(1):18–28. doi:10.​1007/​s12020-012-9660-9 CrossRefPubMed

go back to reference Mete O, Asa SL (2013) Therapeutic implications of accurate classification of pituitary adenomas. Semin Diagn Pathol 30(3):158–164. doi:10.1053/j.semdp.2013.06.002 CrossRefPubMed Mete O, Asa SL (2013) Therapeutic implications of accurate classification of pituitary adenomas. Semin Diagn Pathol 30(3):158–164. doi:10.​1053/​j.​semdp.​2013.​06.​002 CrossRefPubMed

go back to reference Horvath E, Kovacs K (2006) Pathology of acromegaly. Neuroendocrinology 83(3–4):161–165. doi:10.1159/000095524 CrossRefPubMed Horvath E, Kovacs K (2006) Pathology of acromegaly. Neuroendocrinology 83(3–4):161–165. doi:10.​1159/​000095524 CrossRefPubMed

go back to reference Kiseljak-Vassiliades K, Carlson N, Borges M, Kleinschmidt-DeMasters BK, Lillehei K, Kerr J, Wierman M (2014) Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine. doi:10.1007/s12020-014-0383-y PubMedPubMedCentral Kiseljak-Vassiliades K, Carlson N, Borges M, Kleinschmidt-DeMasters BK, Lillehei K, Kerr J, Wierman M (2014) Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine. doi:10.​1007/​s12020-014-0383-y PubMedPubMedCentral

go back to reference Saeger W, Honegger J, Theodoropoulou M, Knappe UJ, Schofl C, Petersenn S, Buslei R (2016) Clinical impact of the current WHO classification of pituitary adenomas. Endocr Pathol. doi:10.1007/s12022-016-9418-7 Saeger W, Honegger J, Theodoropoulou M, Knappe UJ, Schofl C, Petersenn S, Buslei R (2016) Clinical impact of the current WHO classification of pituitary adenomas. Endocr Pathol. doi:10.​1007/​s12022-016-9418-7

go back to reference Puig DM (2015) Treatment of acromegaly in the era of personalized and predictive medicine. Clin Endocrinol. doi:10.1111/cen.12731 Puig DM (2015) Treatment of acromegaly in the era of personalized and predictive medicine. Clin Endocrinol. doi:10.​1111/​cen.​12731

go back to reference Cuevas-Ramos D, Carmichael JD, Cooper O, Bonert VS, Gertych A, Mamelak AN, Melmed SA (2014) Structural and functional acromegaly classification. J Clin Endocrinol Metab. doi:10.1210/jc.2014-2468 PubMedCentral Cuevas-Ramos D, Carmichael JD, Cooper O, Bonert VS, Gertych A, Mamelak AN, Melmed SA (2014) Structural and functional acromegaly classification. J Clin Endocrinol Metab. doi:10.​1210/​jc.​2014-2468 PubMedCentral

go back to reference Syro LV, Rotondo F, Ramirez A, Di Ieva A, Sav MA, Restrepo LM, Serna CA, Kovacs K (2015) Progress in the diagnosis and classification of pituitary adenomas. Front Endocrinol (Lausanne) 6:97. doi:10.3389/fendo.2015.00097 Syro LV, Rotondo F, Ramirez A, Di Ieva A, Sav MA, Restrepo LM, Serna CA, Kovacs K (2015) Progress in the diagnosis and classification of pituitary adenomas. Front Endocrinol (Lausanne) 6:97. doi:10.​3389/​fendo.​2015.​00097

go back to reference Gomez-Hernandez K, Ezzat S, Asa SL, Mete O (2015) Clinical implications of accurate subtyping of pituitary adenomas: perspectives from the treating physician. Turk Patoloji Derg 31(Suppl 1):4–17. doi:10.5146/tjpath.2015.01311 PubMed Gomez-Hernandez K, Ezzat S, Asa SL, Mete O (2015) Clinical implications of accurate subtyping of pituitary adenomas: perspectives from the treating physician. Turk Patoloji Derg 31(Suppl 1):4–17. doi:10.​5146/​tjpath.​2015.​01311 PubMed

go back to reference Sano T, Ohshima T, Yamada S (1991) Expression of glycoprotein hormones and intracytoplasmic distribution of cytokeratin in growth hormone-producing pituitary adenomas. Pathol Res Pract 187(5):530–533. doi:10.1016/s0344-0338(11)80135-4 CrossRefPubMed Sano T, Ohshima T, Yamada S (1991) Expression of glycoprotein hormones and intracytoplasmic distribution of cytokeratin in growth hormone-producing pituitary adenomas. Pathol Res Pract 187(5):530–533. doi:10.​1016/​s0344-0338(11)80135-4 CrossRefPubMed

go back to reference Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, Rayhan N, Rahman MM, Yamada S (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19(2):82–91. doi:10.1007/s12022-008-9029-z CrossRefPubMed Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, Rayhan N, Rahman MM, Yamada S (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19(2):82–91. doi:10.​1007/​s12022-008-9029-z CrossRefPubMed

go back to reference Yamada S, Aiba T, Sano T, Kovacs K, Shishiba Y, Sawano S, Takada K (1993) Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery 33(1):20–27CrossRefPubMed Yamada S, Aiba T, Sano T, Kovacs K, Shishiba Y, Sawano S, Takada K (1993) Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery 33(1):20–27CrossRefPubMed

go back to reference Mori R, Inoshita N, Takahashi-Fujigasaki J, Joki T, Nishioka H, Abe T, Fujii T, Yamada S (2013) Clinicopathological features of growth hormone-producing pituitary adenomas in 242 acromegaly patients: classification according to hormone production and cytokeratin distribution. ISRN Endocrinol 2013:723432. doi:10.1155/2013/723432 CrossRefPubMedPubMedCentral Mori R, Inoshita N, Takahashi-Fujigasaki J, Joki T, Nishioka H, Abe T, Fujii T, Yamada S (2013) Clinicopathological features of growth hormone-producing pituitary adenomas in 242 acromegaly patients: classification according to hormone production and cytokeratin distribution. ISRN Endocrinol 2013:723432. doi:10.​1155/​2013/​723432 CrossRefPubMedPubMedCentral

go back to reference Chanson P, Salenave S, Kamenicky P, Cazabat L, Young J (2009) Pituitary tumours: acromegaly. Best Pract Res Clin Endocrinol Metab 23(5):555–574. doi:10.1016/j.beem.2009.05.010 CrossRefPubMed Chanson P, Salenave S, Kamenicky P, Cazabat L, Young J (2009) Pituitary tumours: acromegaly. Best Pract Res Clin Endocrinol Metab 23(5):555–574. doi:10.​1016/​j.​beem.​2009.​05.​010 CrossRefPubMed

go back to reference Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156(2):203–216. doi:10.1530/eje.1.02326 CrossRefPubMed Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156(2):203–216. doi:10.​1530/​eje.​1.​02326 CrossRefPubMed

go back to reference Xu B, Sano T, Yoshimoto K, Yamada S (2002) Downregulation of E-cadherin and its undercoat proteins in pituitary growth hormone cell adenomas with prominent fibrous bodies. Endocr Pathol 13(4):341–351CrossRefPubMed Xu B, Sano T, Yoshimoto K, Yamada S (2002) Downregulation of E-cadherin and its undercoat proteins in pituitary growth hormone cell adenomas with prominent fibrous bodies. Endocr Pathol 13(4):341–351CrossRefPubMed

go back to reference Nishioka H, Haraoka J, Akada K (2003) Fibrous bodies are associated with lower GH production and decreased expression of E-cadherin in GH-producing pituitary adenomas. Clin Endocrinol 59(6):768–772. doi:10.1046/j.1365-2265.2003.01921.x CrossRef Nishioka H, Haraoka J, Akada K (2003) Fibrous bodies are associated with lower GH production and decreased expression of E-cadherin in GH-producing pituitary adenomas. Clin Endocrinol 59(6):768–772. doi:10.​1046/​j.​1365-2265.​2003.​01921.​x CrossRef

go back to reference Sano T, Rong QZ, Kagawa N, Yamada S (2004) Down-regulation of E-cadherin and catenins in human pituitary growth hormone-producing adenomas. Front Horm Res 32:127–132CrossRefPubMed Sano T, Rong QZ, Kagawa N, Yamada S (2004) Down-regulation of E-cadherin and catenins in human pituitary growth hormone-producing adenomas. Front Horm Res 32:127–132CrossRefPubMed

go back to reference Fougner SL, Lekva T, Borota OC, Hald JK, Bollerslev J, Berg JP (2010) The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J Clin Endocrinol Metab 95(5):2334–2342. doi:10.1210/jc.2009-2197 CrossRefPubMed Fougner SL, Lekva T, Borota OC, Hald JK, Bollerslev J, Berg JP (2010) The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J Clin Endocrinol Metab 95(5):2334–2342. doi:10.​1210/​jc.​2009-2197 CrossRefPubMed

go back to reference Zhou K, Jin H, Luo Y (2013) Expression and significance of E-cadherin and beta-catenins in pituitary adenoma. Int J Surg Pathol 21(4):363–367. doi:10.1177/1066896912471850 CrossRefPubMed Zhou K, Jin H, Luo Y (2013) Expression and significance of E-cadherin and beta-catenins in pituitary adenoma. Int J Surg Pathol 21(4):363–367. doi:10.​1177/​1066896912471850​ CrossRefPubMed

go back to reference Mete O, Asa SL (2012) Clinicopathological correlations in pituitary adenomas. Brain Pathol 22(4):443–453. doi:10.1111/j.1750-3639.2012.00599.x CrossRefPubMed Mete O, Asa SL (2012) Clinicopathological correlations in pituitary adenomas. Brain Pathol 22(4):443–453. doi:10.​1111/​j.​1750-3639.​2012.​00599.​x CrossRefPubMed

go back to reference Vidal S, Syro L, Horvath E, Uribe H, Kovacs K (1999) Ultrastructural and immunoelectron microscopic study of three unusual plurihormonal pituitary adenomas. Ultrastruct Pathol 23(3):141–148CrossRefPubMed Vidal S, Syro L, Horvath E, Uribe H, Kovacs K (1999) Ultrastructural and immunoelectron microscopic study of three unusual plurihormonal pituitary adenomas. Ultrastruct Pathol 23(3):141–148CrossRefPubMed

go back to reference Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Lloyd RV, Young WF Jr (2009) Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol 71(1):92–99. doi:10.1111/j.1365-2265.2008.03514.x CrossRef Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Lloyd RV, Young WF Jr (2009) Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol 71(1):92–99. doi:10.​1111/​j.​1365-2265.​2008.​03514.​x CrossRef

go back to reference Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F, Ezzat S, Asa SL (2016) Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Mod Pathol Off J U S Can Academy of Pathol Inc 29(2):131–142. doi:10.1038/modpathol.2015.151 Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F, Ezzat S, Asa SL (2016) Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Mod Pathol Off J U S Can Academy of Pathol Inc 29(2):131–142. doi:10.​1038/​modpathol.​2015.​151

go back to reference Garby L, Caron P, Claustrat F, Chanson P, Tabarin A, Rohmer V, Arnault G, Bonnet F, Chabre O, Christin-Maitre S, du-Boullay H, Murat A, Nakib I, Sadoul JL, Sassolas G, Claustrat B, Raverot G, Borson-Chazot F, GTE (2012) Clinical characteristics and outcome of acromegaly induced by ectopic secretion of growth hormone-releasing hormone (GHRH): a French nationwide series of 21 cases. J Clin Endocrinol Metab 97(6):2093–2104. doi:10.1210/jc.2011-2930 CrossRefPubMed Garby L, Caron P, Claustrat F, Chanson P, Tabarin A, Rohmer V, Arnault G, Bonnet F, Chabre O, Christin-Maitre S, du-Boullay H, Murat A, Nakib I, Sadoul JL, Sassolas G, Claustrat B, Raverot G, Borson-Chazot F, GTE (2012) Clinical characteristics and outcome of acromegaly induced by ectopic secretion of growth hormone-releasing hormone (GHRH): a French nationwide series of 21 cases. J Clin Endocrinol Metab 97(6):2093–2104. doi:10.​1210/​jc.​2011-2930 CrossRefPubMed

go back to reference Trouillas J, Labat-Moleur F, Sturm N, Kujas M, Heymann MF, Figarella-Branger D, Patey M, Mazucca M, Decullier E, Verges B, Chabre O, Calender A (2008) Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol 32(4):534–543. doi:10.1097/PAS.0b013e31815ade45 CrossRefPubMed Trouillas J, Labat-Moleur F, Sturm N, Kujas M, Heymann MF, Figarella-Branger D, Patey M, Mazucca M, Decullier E, Verges B, Chabre O, Calender A (2008) Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol 32(4):534–543. doi:10.​1097/​PAS.​0b013e31815ade45​ CrossRefPubMed

go back to reference Salenave S, Boyce AM, Collins MT, Chanson P (2014) Acromegaly and McCune-Albright syndrome. J Clin Endocrinol Metab 99(6):1955–1969. doi:10.1210/jc.2013-3826 CrossRefPubMedPubMedCentral Salenave S, Boyce AM, Collins MT, Chanson P (2014) Acromegaly and McCune-Albright syndrome. J Clin Endocrinol Metab 99(6):1955–1969. doi:10.​1210/​jc.​2013-3826 CrossRefPubMedPubMedCentral

go back to reference Iacovazzo D, Caswell R, Bunce B, Jose S, Yuan B, Hernandez-Ramirez LC, Kapur S, Caimari F, Evanson J, Ferrau F, Dang MN, Gabrovska P, Larkin SJ, Ansorge O, Rodd C, Vance ML, Ramirez-Renteria C, Mercado M, Goldstone AP, Buchfelder M, Burren CP, Gurlek A, Dutta P, Choong CS, Cheetham T, Trivellin G, Stratakis CA, Lopes MB, Grossman AB, Trouillas J, Lupski JR, Ellard S, Sampson JR, Roncaroli F, Korbonits M (2016) Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. Acta neuropathologica communications 4(1):56. doi:10.1186/s40478-016-0328-1 CrossRefPubMedPubMedCentral Iacovazzo D, Caswell R, Bunce B, Jose S, Yuan B, Hernandez-Ramirez LC, Kapur S, Caimari F, Evanson J, Ferrau F, Dang MN, Gabrovska P, Larkin SJ, Ansorge O, Rodd C, Vance ML, Ramirez-Renteria C, Mercado M, Goldstone AP, Buchfelder M, Burren CP, Gurlek A, Dutta P, Choong CS, Cheetham T, Trivellin G, Stratakis CA, Lopes MB, Grossman AB, Trouillas J, Lupski JR, Ellard S, Sampson JR, Roncaroli F, Korbonits M (2016) Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. Acta neuropathologica communications 4(1):56. doi:10.​1186/​s40478-016-0328-1 CrossRefPubMedPubMedCentral

go back to reference Schernthaner-Reiter MH, Trivellin G, Stratakis CA (2016) MEN1, MEN4, and Carney Complex: pathology and Molecular Genetics. Neuroendocrinology 103(1):18–31. doi:10.1159/000371819 CrossRefPubMed Schernthaner-Reiter MH, Trivellin G, Stratakis CA (2016) MEN1, MEN4, and Carney Complex: pathology and Molecular Genetics. Neuroendocrinology 103(1):18–31. doi:10.​1159/​000371819 CrossRefPubMed

go back to reference Chinezu L, Jouanneau E, Vasiljevic A, Trouillas J, Raverot G (2013) Silent GH pituitary tumor: diagnostic and therapeutic challenges. Ann Endocrinol 74(5–6):491–495. doi:10.1016/j.ando.2013.09.003 CrossRef Chinezu L, Jouanneau E, Vasiljevic A, Trouillas J, Raverot G (2013) Silent GH pituitary tumor: diagnostic and therapeutic challenges. Ann Endocrinol 74(5–6):491–495. doi:10.​1016/​j.​ando.​2013.​09.​003 CrossRef

go back to reference Cooper O, Melmed S (2012) Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Pract Res Clin Endocrinol Metab 26(4):447–460. doi:10.1016/j.beem.2012.01.002 CrossRefPubMedPubMedCentral Cooper O, Melmed S (2012) Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Pract Res Clin Endocrinol Metab 26(4):447–460. doi:10.​1016/​j.​beem.​2012.​01.​002 CrossRefPubMedPubMedCentral

go back to reference Mayson SE, Snyder PJ (2014) Silent (clinically nonfunctioning) pituitary adenomas. J Neurooncol 117(3):429–436. doi:10.1007/s11060-014-1425-2 CrossRefPubMed Mayson SE, Snyder PJ (2014) Silent (clinically nonfunctioning) pituitary adenomas. J Neurooncol 117(3):429–436. doi:10.​1007/​s11060-014-1425-2 CrossRefPubMed

go back to reference Mohammed S, Syro L, Abad V, Salehi F, Horvath E, Scheithauer BW, Kovacs K, Cusimano M (2009) Silent somatotroph adenoma of the pituitary in an adolescent. Can J Neurol Sci 36(1):123–125CrossRefPubMed Mohammed S, Syro L, Abad V, Salehi F, Horvath E, Scheithauer BW, Kovacs K, Cusimano M (2009) Silent somatotroph adenoma of the pituitary in an adolescent. Can J Neurol Sci 36(1):123–125CrossRefPubMed

go back to reference Sav A, Syro LV, Scheithauer BW, Rotondo F, Builes CA, Horvath E, Kovacs K (2012) Silent somatotroph adenoma: a morphologic, immunohistochemical and electron microscopic study: a case report. J Med Cases. doi:10.4021/jmc416w Sav A, Syro LV, Scheithauer BW, Rotondo F, Builes CA, Horvath E, Kovacs K (2012) Silent somatotroph adenoma: a morphologic, immunohistochemical and electron microscopic study: a case report. J Med Cases. doi:10.​4021/​jmc416w

go back to reference Vieira Neto L, Chimelli L, Pereira PJ, Gasparetto EL, Bines J, Wildemberg LE, Gadelha MR (2013) The role of temozolomide in the treatment of a patient with a pure silent pituitary somatotroph carcinoma. Endocr Pract: Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 19(6):e145–149. doi:10.4158/ep12400.cr CrossRef Vieira Neto L, Chimelli L, Pereira PJ, Gasparetto EL, Bines J, Wildemberg LE, Gadelha MR (2013) The role of temozolomide in the treatment of a patient with a pure silent pituitary somatotroph carcinoma. Endocr Pract: Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 19(6):e145–149. doi:10.​4158/​ep12400.​cr CrossRef

go back to reference Lloyd RV, Kovacs K, Young WF Jr, Farrell W, Asa SL, Trouillas J, Kontogeorgos G, Sano T, Scheithauer BW, Hern E (2004) Pituitary tumors: introduction. In: DeLlelis RA, Lloyd RV, Heitz PU, Eng C (eds) Pathology and Genetics of Tumours of Endocrine Organs. IARC press, Lyon, pp 10–13CrossRef Lloyd RV, Kovacs K, Young WF Jr, Farrell W, Asa SL, Trouillas J, Kontogeorgos G, Sano T, Scheithauer BW, Hern E (2004) Pituitary tumors: introduction. In: DeLlelis RA, Lloyd RV, Heitz PU, Eng C (eds) Pathology and Genetics of Tumours of Endocrine Organs. IARC press, Lyon, pp 10–13CrossRef

go back to reference Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T, Cornelius A, Dufour H, Jouanneau E, Francois P, Galland F, Mougel F, Chapuis F, Villeneuve L, Maurage CA, Figarella-Branger D, Raverot G, Barlier A, Bernier M, Bonnet F, Borson-Chazot F, Brassier G, Caulet-Maugendre S, Chabre O, Chanson P, Cottier JF, Delemer B, Delgrange E, Di Tommaso L, Eimer S, Gaillard S, Jan M, Girard JJ, Lapras V, Loiseau H, Passagia JG, Patey M, Penfornis A, Poirier JY, Perrin G, Tabarin A (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126(1):123–135. doi:10.1007/s00401-013-1084-y CrossRefPubMed Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T, Cornelius A, Dufour H, Jouanneau E, Francois P, Galland F, Mougel F, Chapuis F, Villeneuve L, Maurage CA, Figarella-Branger D, Raverot G, Barlier A, Bernier M, Bonnet F, Borson-Chazot F, Brassier G, Caulet-Maugendre S, Chabre O, Chanson P, Cottier JF, Delemer B, Delgrange E, Di Tommaso L, Eimer S, Gaillard S, Jan M, Girard JJ, Lapras V, Loiseau H, Passagia JG, Patey M, Penfornis A, Poirier JY, Perrin G, Tabarin A (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126(1):123–135. doi:10.​1007/​s00401-013-1084-y CrossRefPubMed

go back to reference Heaney AP (2011) Pituitary Carcinoma: difficult Diagnosis and Treatment. J Clin Endocrinol Metabol 96(12):3649–3660. doi:10.1210/jc.2011-2031 CrossRef Heaney AP (2011) Pituitary Carcinoma: difficult Diagnosis and Treatment. J Clin Endocrinol Metabol 96(12):3649–3660. doi:10.​1210/​jc.​2011-2031 CrossRef

go back to reference Heaney A (2014) Management of aggressive pituitary adenomas and pituitary carcinomas. J Neurooncol 117(3):459–468. doi:10.1007/s11060-014-1413-6 CrossRefPubMed Heaney A (2014) Management of aggressive pituitary adenomas and pituitary carcinomas. J Neurooncol 117(3):459–468. doi:10.​1007/​s11060-014-1413-6 CrossRefPubMed

go back to reference Bengtsson D, Schroder HD, Andersen M, Maiter D, Berinder K, Rasmussen UF, Rasmussen AK, Johannsson G, Hoybye C, van der Lely AJ, Petersson M, Ragnarsson O, Burman P (2015) Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab 100(4):1689–1698. doi:10.1210/jc.2014-4350 CrossRefPubMed Bengtsson D, Schroder HD, Andersen M, Maiter D, Berinder K, Rasmussen UF, Rasmussen AK, Johannsson G, Hoybye C, van der Lely AJ, Petersson M, Ragnarsson O, Burman P (2015) Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab 100(4):1689–1698. doi:10.​1210/​jc.​2014-4350 CrossRefPubMed

go back to reference Lehr H-A, Folpe A, Yaziji H, Kommoss F, Gown AM (2000) Cytokeratin 8 immunostaining pattern and E-cadherinexpression distinguish lobular from ductal breast carcinoma. Am J Clin Pathol 114(2):190–196. doi:10.1309/cpux-kweh-7b26-ye19 CrossRefPubMed Lehr H-A, Folpe A, Yaziji H, Kommoss F, Gown AM (2000) Cytokeratin 8 immunostaining pattern and E-cadherinexpression distinguish lobular from ductal breast carcinoma. Am J Clin Pathol 114(2):190–196. doi:10.​1309/​cpux-kweh-7b26-ye19 CrossRefPubMed

go back to reference Asa SL, Digiovanni R, Jiang J, Ward ML, Loesch K, Yamada S, Sano T, Yoshimoto K, Frank SJ, Ezzat S (2007) A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res 67(15):7505–7511. doi:10.1158/0008-5472.can-07-0219 CrossRefPubMed Asa SL, Digiovanni R, Jiang J, Ward ML, Loesch K, Yamada S, Sano T, Yoshimoto K, Frank SJ, Ezzat S (2007) A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res 67(15):7505–7511. doi:10.​1158/​0008-5472.​can-07-0219 CrossRefPubMed

go back to reference Fougner SL, Casar-Borota O, Heck A, Berg JP, Bollerslev J (2012) Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol 76(1):96–102. doi:10.1111/j.1365-2265.2011.04163.x CrossRef Fougner SL, Casar-Borota O, Heck A, Berg JP, Bollerslev J (2012) Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol 76(1):96–102. doi:10.​1111/​j.​1365-2265.​2011.​04163.​x CrossRef

go back to reference Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M (2013) Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary 16(4):490–498. doi:10.1007/s11102-012-0445-1 CrossRefPubMed Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M (2013) Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary 16(4):490–498. doi:10.​1007/​s11102-012-0445-1 CrossRefPubMed

go back to reference Mayr B, Buslei R, Theodoropoulou M, Stalla GK, Buchfelder M, Schöfl C (2013) Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. Eur J Endocrinol 169(4):391–400. doi:10.1530/eje-13-0134 CrossRefPubMed Mayr B, Buslei R, Theodoropoulou M, Stalla GK, Buchfelder M, Schöfl C (2013) Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. Eur J Endocrinol 169(4):391–400. doi:10.​1530/​eje-13-0134 CrossRefPubMed

go back to reference Ballman KV (2015) Biomarker: predictive or Prognostic? J Clin Oncol: Off J Am Soc Clin Oncol 33(33):3968–3971. doi:10.1200/jco.2015.63.3651 CrossRef Ballman KV (2015) Biomarker: predictive or Prognostic? J Clin Oncol: Off J Am Soc Clin Oncol 33(33):3968–3971. doi:10.​1200/​jco.​2015.​63.​3651 CrossRef

go back to reference Nalejska E, Maczynska E, Lewandowska MA (2014) Prognostic and predictive biomarkers: tools in personalized oncology. Mol Diagn Ther 18(3):273–284. doi:10.1007/s40291-013-0077-9 CrossRefPubMedPubMedCentral Nalejska E, Maczynska E, Lewandowska MA (2014) Prognostic and predictive biomarkers: tools in personalized oncology. Mol Diagn Ther 18(3):273–284. doi:10.​1007/​s40291-013-0077-9 CrossRefPubMedPubMedCentral

go back to reference Syro LV, Rotondo F, Kovacs K (2015) Biomarkers of acromegaly. Endocrine 49(1):4–5. doi:10.1007/s12020-015-0579-9 CrossRefPubMed Syro LV, Rotondo F, Kovacs K (2015) Biomarkers of acromegaly. Endocrine 49(1):4–5. doi:10.​1007/​s12020-015-0579-9 CrossRefPubMed

go back to reference Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S (2005) The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90(11):6290–6295. doi:10.1210/jc.2005-0998 CrossRefPubMed Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S (2005) The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90(11):6290–6295. doi:10.​1210/​jc.​2005-0998 CrossRefPubMed

go back to reference Taboada GF, Luque RM, Neto LV, de Machado OE, Sbaffi BC, Domingues RC, Marcondes JB, Chimelli LM, Fontes R, Niemeyer P, de Carvalho DP, Kineman RD, Gadelha MR (2008) Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol 158(3):295–303. doi:10.1530/eje-07-0562 CrossRefPubMed Taboada GF, Luque RM, Neto LV, de Machado OE, Sbaffi BC, Domingues RC, Marcondes JB, Chimelli LM, Fontes R, Niemeyer P, de Carvalho DP, Kineman RD, Gadelha MR (2008) Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol 158(3):295–303. doi:10.​1530/​eje-07-0562 CrossRefPubMed

go back to reference Colao A, Auriemma RS, Lombardi G, Pivonello R (2011) Resistance to somatostatin analogs in acromegaly. Endocr Rev 32(2):247–271. doi:10.1210/er.2010-0002 CrossRefPubMed Colao A, Auriemma RS, Lombardi G, Pivonello R (2011) Resistance to somatostatin analogs in acromegaly. Endocr Rev 32(2):247–271. doi:10.​1210/​er.​2010-0002 CrossRefPubMed

go back to reference Chinezu L, Vasiljevic A, Jouanneau E, Francois P, Borda A, Trouillas J, Raverot G (2014) Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies. Hum Pathol 45(1):71–77. doi:10.1016/j.humpath.2013.08.007 CrossRefPubMed Chinezu L, Vasiljevic A, Jouanneau E, Francois P, Borda A, Trouillas J, Raverot G (2014) Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies. Hum Pathol 45(1):71–77. doi:10.​1016/​j.​humpath.​2013.​08.​007 CrossRefPubMed

go back to reference Kiseljak-Vassiliades K, Xu M, Mills TS, Smith EE, Silveira LJ, Lillehei KO, Kerr JM, Kleinschmidt-DeMasters BK, Wierman ME (2015) Differential somatostatin receptor (SSTR) 1–5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors. Mol Cell Endocrinol 417:73–83. doi:10.1016/j.mce.2015.09.016 CrossRefPubMedPubMedCentral Kiseljak-Vassiliades K, Xu M, Mills TS, Smith EE, Silveira LJ, Lillehei KO, Kerr JM, Kleinschmidt-DeMasters BK, Wierman ME (2015) Differential somatostatin receptor (SSTR) 1–5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors. Mol Cell Endocrinol 417:73–83. doi:10.​1016/​j.​mce.​2015.​09.​016 CrossRefPubMedPubMedCentral

go back to reference Gatto F, Biermasz NR, Feelders RA, Kros JM, Dogan F, van der Lely AJ, Neggers SJ, Lamberts SW, Pereira AM, Ferone D, Hofland LJ (2016) Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. Eur J Endocrinol 174(5):651–662. doi:10.1530/eje-15-0391 CrossRefPubMed Gatto F, Biermasz NR, Feelders RA, Kros JM, Dogan F, van der Lely AJ, Neggers SJ, Lamberts SW, Pereira AM, Ferone D, Hofland LJ (2016) Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. Eur J Endocrinol 174(5):651–662. doi:10.​1530/​eje-15-0391 CrossRefPubMed

go back to reference Greenman Y, Melmed S (1994) Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79(3):724–729. doi:10.1210/jcem.79.3.7521350 PubMed Greenman Y, Melmed S (1994) Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79(3):724–729. doi:10.​1210/​jcem.​79.​3.​7521350 PubMed

go back to reference Cuevas-Ramos D, Fleseriu M (2014) Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. J Mol Endocrinol 52(3):R223–240. doi:10.1530/jme-14-0011 CrossRefPubMed Cuevas-Ramos D, Fleseriu M (2014) Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. J Mol Endocrinol 52(3):R223–240. doi:10.​1530/​jme-14-0011 CrossRefPubMed

go back to reference Iacovazzo D, Carlsen E, Lugli F, Chiloiro S, Piacentini S, Bianchi A, Giampietro A, Mormando M, Clear AJ, Doglietto F, Anile C, Maira G, Lauriola L, Rindi G, Roncaroli F, Pontecorvi A, Korbonits M, De Marinis L (2016) Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol 174(2):241–250. doi:10.1530/eje-15-0832 CrossRefPubMed Iacovazzo D, Carlsen E, Lugli F, Chiloiro S, Piacentini S, Bianchi A, Giampietro A, Mormando M, Clear AJ, Doglietto F, Anile C, Maira G, Lauriola L, Rindi G, Roncaroli F, Pontecorvi A, Korbonits M, De Marinis L (2016) Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol 174(2):241–250. doi:10.​1530/​eje-15-0832 CrossRefPubMed

go back to reference Saeger W, Petersenn S, Schofl C, Knappe UJ, Theodoropoulou M, Buslei R, Honegger J (2016) Emerging histopathological and genetic parameters of pituitary adenomas: clinical impact and recommendation for future WHO classification. Endocr Pathol. doi:10.1007/s12022-016-9419-6 Saeger W, Petersenn S, Schofl C, Knappe UJ, Theodoropoulou M, Buslei R, Honegger J (2016) Emerging histopathological and genetic parameters of pituitary adenomas: clinical impact and recommendation for future WHO classification. Endocr Pathol. doi:10.​1007/​s12022-016-9419-6

go back to reference Casar-Borota O, Heck A, Schulz S, Nesland JM, Ramm-Pettersen J, Lekva T, Alafuzoff I, Bollerslev J (2013) Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. J Clin Endocrinol Metab 98(11):E1730–1739. doi:10.1210/jc.2013-2145 CrossRefPubMed Casar-Borota O, Heck A, Schulz S, Nesland JM, Ramm-Pettersen J, Lekva T, Alafuzoff I, Bollerslev J (2013) Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. J Clin Endocrinol Metab 98(11):E1730–1739. doi:10.​1210/​jc.​2013-2145 CrossRefPubMed

go back to reference Theodoropoulou M, Tichomirowa MA, Sievers C, Yassouridis A, Arzberger T, Hougrand O, Deprez M, Daly AF, Petrossians P, Pagotto U, Beckers A, Stalla GK (2009) Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. Int J Cancer 125(9):2122–2126. doi:10.1002/ijc.24602 CrossRefPubMed Theodoropoulou M, Tichomirowa MA, Sievers C, Yassouridis A, Arzberger T, Hougrand O, Deprez M, Daly AF, Petrossians P, Pagotto U, Beckers A, Stalla GK (2009) Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. Int J Cancer 125(9):2122–2126. doi:10.​1002/​ijc.​24602 CrossRefPubMed

go back to reference Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneanu L (1999) Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 10(3):229–235CrossRefPubMed Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneanu L (1999) Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 10(3):229–235CrossRefPubMed

go back to reference Kleinschmidt-DeMasters BK, Lopes MB (2013) Update on hypophysitis and TTF-1 expressing sellar region masses. Brain Pathol 23(5):495–514. doi:10.1111/bpa.12068 CrossRefPubMed Kleinschmidt-DeMasters BK, Lopes MB (2013) Update on hypophysitis and TTF-1 expressing sellar region masses. Brain Pathol 23(5):495–514. doi:10.​1111/​bpa.​12068 CrossRefPubMed

go back to reference Naritaka H, Kameya T, Sato Y, Furuhata S, Otani M, Kawase T (1999) Morphological characterization and subtyping of silent somatotroph adenomas. Pituitary 1(3–4):233–241CrossRefPubMed Naritaka H, Kameya T, Sato Y, Furuhata S, Otani M, Kawase T (1999) Morphological characterization and subtyping of silent somatotroph adenomas. Pituitary 1(3–4):233–241CrossRefPubMed

go back to reference Chauvet N, Romano N, Meunier AC, Galibert E, Fontanaud P, Mathieu MN, Osterstock G, Osterstock P, Baccino E, Rigau V, Loiseau H, Bouillot-Eimer S, Barlier A, Mollard P, Coutry N (2016) Combining cadherin expression with molecular markers discriminates invasiveness in growth hormone and prolactin pituitary adenomas. J Neuroendocrinol. doi:10.1111/jne.12352 PubMed Chauvet N, Romano N, Meunier AC, Galibert E, Fontanaud P, Mathieu MN, Osterstock G, Osterstock P, Baccino E, Rigau V, Loiseau H, Bouillot-Eimer S, Barlier A, Mollard P, Coutry N (2016) Combining cadherin expression with molecular markers discriminates invasiveness in growth hormone and prolactin pituitary adenomas. J Neuroendocrinol. doi:10.​1111/​jne.​12352 PubMed

go back to reference Ben-Shlomo A, Melmed S (2010) Pituitary somatostatin receptor signaling. Trends Endocrinol Metab 21(3):123–133. doi:10.1016/j.tem.2009.12.003 CrossRefPubMedPubMedCentral Ben-Shlomo A, Melmed S (2010) Pituitary somatostatin receptor signaling. Trends Endocrinol Metab 21(3):123–133. doi:10.​1016/​j.​tem.​2009.​12.​003 CrossRefPubMedPubMedCentral

go back to reference Fougner SL, Borota OC, Berg JP, Hald JK, Ramm-Pettersen J, Bollerslev J (2008) The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin Endocrinol 68(3):458–465. doi:10.1111/j.1365-2265.2007.03065.x CrossRef Fougner SL, Borota OC, Berg JP, Hald JK, Ramm-Pettersen J, Bollerslev J (2008) The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin Endocrinol 68(3):458–465. doi:10.​1111/​j.​1365-2265.​2007.​03065.​x CrossRef

go back to reference Chahal HS, Trivellin G, Leontiou CA, Alband N, Fowkes RC, Tahir A, Igreja SC, Chapple JP, Jordan S, Lupp A, Schulz S, Ansorge O, Karavitaki N, Carlsen E, Wass JA, Grossman AB, Korbonits M (2012) Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab 97(8):E1411–1420. doi:10.1210/jc.2012-1111 CrossRefPubMed Chahal HS, Trivellin G, Leontiou CA, Alband N, Fowkes RC, Tahir A, Igreja SC, Chapple JP, Jordan S, Lupp A, Schulz S, Ansorge O, Karavitaki N, Carlsen E, Wass JA, Grossman AB, Korbonits M (2012) Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab 97(8):E1411–1420. doi:10.​1210/​jc.​2012-1111 CrossRefPubMed